RPG LIFE SCIENCES LTD (NSE:RPGL) Q4 FY23 Earnings Concall dated May. 02, 2023. Corporate Participants: Yugal Sikri -- Managing Director Analysts: Sudarshan Padmanabhan -- JM Financial
RPG LIFE SCIENCES LTD (RPGL) Q4 FY23 Earnings Concall Transcript
Categories
Health Care
Aarti Drugs Limited (AARTIDRUGS) Q4 FY23 Earnings Concall Transcript
Aarti Drugs Limited (NSE:AARTIDRUGS) Q4 FY23 Earnings Concall dated May. 02, 2023. Corporate Participants: Adhish Patil -- Chief Financial Officer Harshit M. Savla -- Joint Managing
Glenmark Life Sciences Limited (GLS) Q4 FY23 Earnings Concall Transcript
Glenmark Life Sciences Limited (NSE:GLS) Q4 FY23 Earnings Concall dated Apr. 28, 2023. Corporate Participants: Soumi Rao -- General Manager, Corporate Communications Yasir Rawjee -- Managing
Laurus Labs Limited Q4 FY23 Earnings Conference Call Insights
https://youtu.be/5Vtl-XMN8qg Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY23 Earnings Concall Management Update: [00:09:24]LAURUSLABS said it invested in expanding non-ARV formulation
Laurus Labs Limited (LAURUSLABS) Q4 FY23 Earnings Concall Transcript
Laurus Labs Limited (NSE:LAURUSLABS) Q4 FY23 Earnings Concall dated Apr. 27, 2023. Corporate Participants: Satyanarayana Chava -- Founder & Chief Executive Officer V V
Dhampur Bio Organics Ltd (DBOL) Q4 FY23 Earnings Concall Transcript
Dhampur Bio Organics Ltd (NSE:DBOL) Q4 FY23 Earnings Concall dated Apr. 27, 2023. Corporate Participants: Mr. Navin Agrawal -- Head of Institutional Equities Nalin
Syngene International Ltd (SYNGENE) Q4 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE:SYNGENE) Q4 FY23 Earnings Concall dated Apr. 27, 2023. Corporate Participants: Avantika Mishra -- Investor Relations Jonathan Hunt -- Managing Director and Chief
Laurus Labs Limited Q4FY23 Earnings
To meet the demands of the international pharmaceutical industry, Laurus Labs primarily provides a comprehensive and integrated portfolio of Active Pharmaceutical Ingredients
Syngene reported 21 percent rise in its Q4FY23 net profit
Syngene reported Total revenue for Q4 FY23 of ₹994 Crore, up from ₹759 Crore year on year, a growth of 31%.While, consolidated
Syngene International Q4FY23 results out, revenue rises by 31%
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Nath Bio-Genes (India) Limited (NATHBIOGEN) Q4 FY23 Earnings Concall Transcript
Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Q4 FY23 Earnings Concall dated Apr. 24, 2023. Corporate Participants: Unidentified Speaker -- Devinder Khurana -- Chief Financial Officer Satish
Panacea Biotec Limited: Making India Healthier
Panacea Biotec Limited is an Indian pharmaceutical company that is engaged in research, development, and manufacturing of pharmaceuticals, vaccines, and natural products.
Shalby Ltd: A rising star in the Anthroplasty surgery
“I am happy to report that our hospital business continued to deliver consistent performance in all key operational and financial parameters with
Can Jubilant Pharmova leverage their position?
“In FY24, Company’s profitability is expected to improve, driven by growth in Radiopharmaceuticals, Allergy Immunotherapy and CDMO Sterile Injectables businesses. Recovery in
Glenmark Pharmaceuticals: An Uphill Battle
“Strategic priority is to enhance our free cash generation and further debt reduction and we continue discussion with potential partners for out-licensing
Neuland Laboratories Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Neuland Laboratories Limited (NEULANDLAB) Q3 FY23 Earnings Concall Management Update: [00:05:35] NEULANDLAB said its raw material prices are becoming
Sequent Scientific Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Sequent Scientific Limited (SEQUENT) Q3 FY23 Earnings Concall Management Update: [00:05:37] SEQUENT said that in the API business, the
Supriya Lifescience Ltd Q3 FY23 Earnings Conference Call Insights
Key highlights from Supriya Lifescience Ltd (SUPRIYA) Q3 FY23 Earnings Concall Management Update: [00:04:00] SUPRIYA said its primary focus remains on expanding
The Revival of Amrutanjan Healthcare Limited
Amrutanjan’s flagship yellow headache balm is possibly its most successful product. It is also among the first products that the company launched.
Orchid Pharma Ltd Q3 FY23 Earnings Conference Call Insights
Key highlights from Orchid Pharma Ltd (ORCHPHARMA) Q3 FY23 Earnings Concall Q&A Highlights: [00:04:43] Himanshu Upadhyay from o3 Capital asked what changed
Apollo Hospitals Enterprise Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Apollo Hospitals Enterprise Limited (APOLLOHOSP) Q3 FY23 Earnings Concall Management Update: [00:02:04] APOLLOHOSP said it had a good 3Q23,